Register for our free email digests:
Division of Erba Diagnostics Mannheim GMBH
Latest From OctreoPharm Sciences GMBH
Mylan adds more than 900 over-the-counter and generic products to its portfolio with the $9.9bn acquisition of Meda. Astellas finalizes the pursuit of Ocata which it began last November.
A turnaround in Ipsen’s U.S. business is underpinning a transformation at the European mid-sized pharmaceutical company, which is planning to narrow its focus to niche therapeutic areas including gastrointestinal endocrine tumors and antispasticity neurotoxins.
Novartis’s Jimenez calls for new outcomes-based pricing in Europe, and U.K. PM Cameron wants the results of vaccine clinical trials to be open and transparent post-Ebola, while patients gain pre-approval access to Bristol’s new PD-1 inhibitor.
This Month's Profile Group: Biotechs Share Endocrine Enthusiasm, features profiles of Atterocor, Crinetics Pharmaceuticals, and OctreoPharm Sciences. Plus these Start-Ups Across Health Care: Biom’Up SA, KemPharm, LIM Innovations, Reflectance Medical, and Trino Therapeutics.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Erba Diagnostics Mannheim GMBH
- Senior Management
Laurence Tisi, PhD, CEO
Hayden Jeffreys, Commercial Dir.
Rob Sprawson, Fin. Dir.
- Contact Info
Phone: 1353 667907
Ely, Cambridgeshire, CB7 4EA
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.